States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...

According to Coherent Market Insights (CMI), the global sickle cell disease treatment market size is expected to expand from USD 3.20 Bn in 2025 to USD 8.81 Bn by 2032, recording a CAGR of 15.6% ...

CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., ...

The Centers for Medicare and Medicaid Services has named 33 states, as well as Washington, D.C., and Puerto Rico, as participants in its Cell and Gene Therapy Access Model, which is designed to treat ...

The model was initially launched by the Biden administration in February 2023, and CMS announced that SCD would be the first focus of the model the following January. This is the ...

CMS has reached agreements with drug manufacturers to provide gene therapies to treat sickle cell disease to Medicaid recipients under a new outcomes-based model. A total of 33 states, including the ...

The US regulator has launched a new national initiative to help Medicaid programs fund gene therapies for sickle cell disease ...

The participating regions are home to 84 percent of sickle cell Medicaid patients who could gain access to gene therapies under outcomes-based agreements.

The Centers for Medicare and Medicaid Services (CMS) has selected 35 participants for its new, voluntary Cell and Gene ...

Safi Biotherapeutics (Safi), a biotechnology company producing stem-cell derived, manufactured human red blood cell (mRBC) ...

SRT CEO Patrick Girondi and Artist and Project Manager Megan Euker with newly restored San Rocco sculpture, Altamura, Italy.

This innovative software, CRISPRware, optimizes guide RNA design for genome editing, supporting research on genetic disorders ...